In Regeneron Pharmaceuticals Inc.’s phase I/II Chord study of 12 children with genetic hearing loss, 10 out of 11 have shown improvements after being treated with a gene therapy. “What is really ...
DelveInsight's Advanced Therapy Medicinal Products Market Insights report provides the current and forecast market analysis, ...
On February 18, 2025, a panel of the U.S. Court of Appeals for the First Circuit unanimously decided that in order to transform an ...
This was the stock's sixth consecutive day of gains.
The general mood among these heavyweight investors is divided, with 62% leaning bullish and 18% bearish. Among these notable ...
Last week, the First Circuit Court of Appeals issued its long-awaited decision in United States v. Regeneron Pharmaceuticals with ...
We recently compiled a list of the 15 Stocks That Will Go to The Moon According to Analysts. In this article, we are going to ...
Lilly expands its Zepbound vial offering, as HIMS pulls back on semaglutide, and other biotech news in today's Readout ...
Ten of 11 children born with a rare form of congenital hearing loss experienced improvements after receiving the company’s ...
Kiniksa plans to initiate a Phase 2/3 clinical trial of KPL-387 in recurrent pericarditis in mid-2025 –– KPL-387 Phase 1 single ascending dose ...
Regeneron's DB-OTO gene therapy shows improved hearing in 10 of 11 children in the CHORD trial, with three reaching ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback